MICHAEL TAYLOR to Disease-Free Survival
This is a "connection" page, showing publications MICHAEL TAYLOR has written about Disease-Free Survival.
Connection Strength
0.385
-
Medulloblastoma molecular dissection: the way toward targeted therapy. Curr Opin Oncol. 2013 Nov; 25(6):674-81.
Score: 0.089
-
Reproducibility of the NanoString 22-gene molecular subgroup assay for improved prognostic prediction of medulloblastoma. Neuropathology. 2018 Oct; 38(5):475-483.
Score: 0.031
-
Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathol. 2017 11; 134(5):705-714.
Score: 0.029
-
Prognostic relevance of miR-124-3p and its target TP53INP1 in pediatric ependymoma. Genes Chromosomes Cancer. 2017 08; 56(8):639-650.
Score: 0.028
-
Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma. Oncotarget. 2016 Aug 16; 7(33):53881-53894.
Score: 0.027
-
Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncol. 2016 04; 17(4):484-495.
Score: 0.026
-
Molecular characterization of choroid plexus tumors reveals novel clinically relevant subgroups. Clin Cancer Res. 2015 Jan 01; 21(1):184-92.
Score: 0.024
-
Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells. Acta Neuropathol. 2014 Dec; 128(6):863-77.
Score: 0.023
-
The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States. Cancer. 2014 Jun 15; 120(12):1830-7.
Score: 0.023
-
Duration of the pre-diagnostic interval in medulloblastoma is subgroup dependent. Pediatr Blood Cancer. 2014 Jul; 61(7):1190-4.
Score: 0.023
-
Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. Lancet Oncol. 2013 May; 14(6):534-42.
Score: 0.021
-
Nestin expression identifies ependymoma patients with poor outcome. Brain Pathol. 2012 Nov; 22(6):848-60.
Score: 0.020
-
FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. J Clin Oncol. 2011 Oct 10; 29(29):3852-61.
Score: 0.019